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It is known that the cytoplasmic zinc finger protein A20 functionally dampens inflammatory signals and apoptosis via inhibition of NF-κB
activation and biochemically acts as a unique ubiquitin-modifying protein with deubiquitinating activity and ubiquitin ligase activity. However,
the molecular mechanisms of A20-modulated signal transduction that influence normal immune responses or tumor immunity have not been
fully elucidated. Using a yeast two-hybrid system to search for proteins interacting with A20, we identified one novel binding protein, Ymer.
Ymer, which has been reported to be highly phosphorylated on tyrosine residues via EGF stimulation, bound to lysine (K)-63-linked
polyubiquitin chain on receptor-interacting serine/threonine-protein kinase 1 (RIP1), which is essential for NF-κB signaling in collaboration with
A20. A luciferase assay showed that NF-κB signaling was down-regulated by overexpression of Ymer, whereas knock-down of Ymer up-
regulated NF-κB signaling even without stimulation. These findings demonstrate that Ymer is likely to be a negative regulator for the NF-κB
signaling pathway.
© 2007 Elsevier B.V. All rights reserved.Keywords: NF-κB; A20; Ymer; RIP1; Ubiquitin1. Introduction
NF-κB is a ubiquitously expressed transcription factor that
induces the expression of genes that regulate diverse cellular
functions such as inflammation, immunity, cell growth and
apoptosis in response to various intra- and extra-cellular sti-
muli [1,2]. NF-κB forms a homo- or hetero-dimeric complex
of subunits that belong to the Rel family, including p105/50
(NF-κB1), p100/52 (NF-κB2), p65 (RelA), RelB and c-Rel,
that share the Rel homology region (RHR), a highly
conserved sequence of 300 amino acids. In a resting state,
NF-κB is retained in the cytoplasm by binding to IκB. In
canonical and non-canonical NF-κB signaling pathways, IκB
phosphorylation and ubiquitination followed by proteasomal⁎ Corresponding author. Tel.: +81 11 706 5899; fax: +81 11 706 5169.
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doi:10.1016/j.bbamcr.2007.09.006degradation leads to the activation of NF-κB. Upon
stimulation such as cytokines, chemokines and pathogens,
the β subunit of IκB kinase (IKK) complex is phosphory-
lated. The activated IKKβ phosphorylates IκBα serine
residues and then IκBα is ubiquitinated by the SCFFbw1
(Skp1-Cul1-F-box ligase containing the F-box protein) E3
ligase and degraded through a proteasome-dependent pathway
[3–6]. The activated NF-κB dimer translocates into the
nucleus and binds the κB sequences in the promoter or
enhancer of target genes [1,2].
NF-κB can be a proapoptotic or antiapoptotic modulator,
depending on cell status or several kinds of stimulus [7]. Two
major apoptotic pathways, the intrinsic pathway that is asso-
ciated with mitochondria and the extrinsic pathway associated
with death receptors (DRs) such as TNF receptor-1 (TNFR1),
are well known. The death domain of TNFR1 promotes both
NF-κB activation and apoptosis via RIP1 [8]. Upon stimulation
with TNFα, RIP1 is first recruited by TNF receptor associated
with death domain protein (TRADD) to TNFR1 and then
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Uev1A and TRAF2 as E2 and E3, respectively. The K63-linked
ubiquitinated RIP1 recruits TAB2 and TAK1 complex and
activates two catalytic subunits of IKK (IKKα/IKKβ), followed
by NF-κB activation [9–12]. Hence, K63-linked ubiquitination
of RIP1 is essential for the activation of NF-κB. As another
signal pathway, TRADD and RIP1 form a complex with Fas-
associated death domain protein (FADD) and caspase-8 in the
cytoplasm, and then the complex initiates apoptosis.
TheK63-linked polyubiquitin chain onRIP1 is hydrolysed by
the ubiquitin-modifying protein A20, seriatim A20 forms a K48-
linked polyubiquitin chain on RIP1, and then RIP1 is degraded
by proteasome, followed by attenuation of NF-κB signaling
[11,13]. A20 is a broadly expressed cytoplasmic protein induced
by TNFα stimulation and has been identified as an inhibitor of
TNF-induced NF-κB activation or apoptosis. A20-deficient cells
fail to terminate TNF-induced NF-κB signaling [14]. A20 has
two ubiquitin-editing domains, one N-terminal ovarian tumor
(OTU) domain and C-terminal seven zinc finger domains, sug-
gesting that A20 possesses a dual function as a ubiquitin chain
exchanger, which is sequential de-ubiquitination and ubiquiti-
nation, to interfere with NF-κB signaling [11]. A20 dampens
NF-κB signaling by deubiquitination of RIP1 and IKK in
cooperation with ABIN1 (A20-binding inhibitor of NF-κB 1)
[15–19]. However, the molecular mechanisms of A20-modu-
lated signal transduction that influence normal immune re-
sponses or tumorigenicity have not been fully elucidated.
In this study, we obtained evidence that A20 interacts with
Ymer, which binds to the K63-linked polyubiquitin chain on
RIP1. We found that the overexpression of Ymer diminishes
NF-κB signaling, whereas the knock-down of endogenousYmer
up-regulates NF-κB signaling, suggesting that Ymer functions
as a negative regulator for NF-κB signaling.
2. Materials and methods
2.1. Cell culture
HEK293T and HeLa cell lines were cultured under an atmosphere of 5%
CO2 at 37 °C in Dulbecco's modified Eagle's medium (Sigma Chemical Co., St.
Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco
BRL, Paisley, UK). Jurkat cells were cultured under the same conditions in
RPMI1640 (Sigma) with 10% FBS. Ba/F3 cell line stably expressing human
TLR4, MD2, CD14 and κB reporter gene, which was kindly provided by K.
Miyake (University of Tokyo), were maintained in RPMI 1640 with 10% FBS
and interleukin 3 (IL-3) at the concentration of 10 ng/ml.
2.2. Cloning of cDNAs and plasmid construction
Human A20 cDNA and Ymer were amplified by PCR from human B cell
cDNA (Clontech Laboratories, Inc. Mountain View, CA). The resulting frag-
ments containing the human A20, Ymer, RIP1, Ubc13 and Uev1A cDNAs were
ligated into the pCR2 vector (Invitrogen, Carlsbad, CA) with FLAG-tag, into the
pcDNA3 vector (Invitrogen) with Myc-tag, into the pCGN-HAvector [42], into
pGEX6P1 (Amersham Biosciences, Piscataway, NJ), into pET30 (Novagen,
Madison, WI) or into pCAGGS vector from Dr. J. Miyazaki (Osaka University)
[43]. Site-directed mutagenesis to generate L116P mutant was performed using
human Ymer cDNA cloned into pBluescript II SK+ (Stratagene, La Jolla, CA) as
a template with a QuikChange kit (Stratagene). The sequence of each con-
structed vector was confirmed by the dideoxy chain termination method with
automated sequencing (Applied Biosystems, Foster City, CA).2.3. Recombinant proteins and antibodies
His-tagged A20 was expressed in the Sf9 insect cell line using a baculovirus
protein expression system (Invitrogen), and His-tagged RIP1, Uev1A and
Ubc13 were expressed in E. coli strain BL21 (DE3) (Invitrogen). The recom-
binant His-tagged proteins were purified by using ProBond metal affinity beads
(Invitrogen). GST-tagged full-length human Ymer was expressed in XL-1 Blue
cells. The protein was purified by GSH-Sepharose beads (Roche, Branchburg,
NJ) and separated from the GST region by PreScisson protease (Amersham
Pharmacia Biotech). The recombinant protein was used as immunogen in
rabbits. Other antibodies used were as follows: mouse monoclonal anti-Myc
antibody (9E10, Roche Molecular Biochemicals), mouse monoclonal anti-HA
antibody (HA.11/16B12, Covance Research Products, Berkeley, CA), mouse
monoclonal anti-FLAG (M2) (Sigma), mouse anti-A20 antibody (59A426,
Merck KGaA, Darmstadt, Germany), mouse anti-ubiquitin antibody (P4D1,
Santa Cruz Biotechnology, Santa Cruz, CA), mouse monoclonal multiubiquitin
antibody (FK2, Nippon Bio-Test Laboratories Inc., Japan), mouse monoclonal
RIP1 antibody (38, BD Transduction Laboratories, San Jose, CA) and mouse
monoclonal HSP90 antibody (68, BD Transduction Laboratories). K63- and
K48-linked polyubiquitin chains were purchased from Boston Biochem (Cam-
bridge, MA), EGF and TNFα were from Upstate, and LPS was from Sigma.
2.4. Yeast two-hybrid screening
Complementary DNAs encoding full lengths of human A20 and Ymer were
fused in-frame to the nucleotide sequence for the LexA domain (BD) in the yeast
two-hybrid vector pBTM116. For yeast two-hybrid screening, the yeast strain
L40 [MATa, his3D200, trp1–901, leu2–3, 112, ade2, LYS2::(lexAop) 4-HIS3I,
URA3::(lexAop) 8-lacZ, gal4, gal80] (Invitrogen) was transformed with a
cDNA library of the human B cell Matchmaker cDNA library (Clontech) using
the lithium acetate method as described previously.
2.5. In vitro ubiquitination assay
In vitro ubiquitination assays were performed as previously described [44].
In brief, reaction mixtures containing either 4 μg of the full-sized recombinant
RIP1 with 0.1 μg recombinant rabbit E1 (Boston Biochem), 1 μg E2s (His-
tagged Uev1A and His-tagged Ubc13), 0.5 U phosphocreatine kinase, 1 μg
ubiquitin (Sigma), 25 mM Tris–HCl, pH 7.5, 120 mM NaCl, 2 mM ATP, 1 mM
MgCl2, 0.3 mM dithiothreitol, and 1 mM creatine phosphate were incubated for
16 h at 30 °C.
2.6. In vitro protein-binding assay
Recombinant proteins (1 μg of K48- or K63-polyubiquitin, 0.75 μg each of
GST, GST-Ymer, GST-Ymer1–64, GST-Ymer1–146, GST-YmerΔ65–134,
4 μg of His6-RIP1) were mixed at 4 °C in 100 μl of protein binding buffer
(25 mM HEPES at pH 7.4, 150 mM KCl, 2 mM MgCl2, 0.5% Triton X-100,
1 mM EGTA, and 1 mg/ml BSA). The binding mixtures were then purified with
glutathione-Sepharose-4B beads (Amersham Pharmacia), and the resulting
precipitates were subjected to SDS-PAGE and immunoblot analysis with anti-
bodies to ubiquitin (1 μg/ml), GST (1 μg/ml) or RIP1 (1 μg/ml).
2.7. Transfection, immunoprecipitation, and immunoblot analysis
HEK293T cells were transfected by the calcium phosphate method. After
48 h, the cells were lysed in a solution containing 50 mM Tris–HCl (pH 7.4),
150 mM NaCl, 1% Nonidet P-40, leupeptin (10 μg/ml), 1 mM phenylmethyl-
sulfonyl fluoride, 400 μM Na3VO4, 400 μM EDTA, 10 mM NaF, and 10 mM
sodium pyrophosphate or were lysed in Laemmli buffer containing 25 mMTris–
HCl (pH 8.3), 192 mM glycine, and 0.1% SDS to solubilize an NP-40-insoluble
compartment. The cell lysates were centrifuged at 16,000×g for 10 min at 4 °C,
and the resulting supernatant was incubated with antibodies for 2 h at 4 °C.
Protein G-Sepharose (Amersham Pharmacia) that had equilibrated with the same
solution was added to the mixture, which was then rotated for 1 h at 4 °C. The
resin was separated by centrifugation, washed four times with ice-cold lysis
buffer, and then boiled in SDS sample buffer. Immunoblot analysis was
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bodies to mouse or rabbit immunoglobulin G (1:10,000 dilution, Promega) and
an enhanced chemiluminescence system (ECL, Amersham Pharmacia).
2.8. Pulse-chase analysis with cycloheximide
Cells were cultured with cycloheximide at the concentration of 50 μg/ml and
then incubated for various times. Cell lysates were then subjected to SDS-PAGE
and immunoblot analysis with anti-FLAG, anti-RIP1, anti-Myc and anti-β-actin
antibodies. Cycloheximide and chloroquinewere purchased fromSigma,MG132
and LLnL were from Boston Biochem (Cambridge, MA), and NH4Cl was from
Wako (Osaka, Japan).
2.9. Retrovirus expression system
Complementary DNAs encoding human wild-type Ymer or YmerL116P
containing FLAG-tags at their N-termini were subcloned into pMX-puro (all
kindly provided by T. Kitamura, University of Tokyo), and the resulting vectors
were used to transfect Plat E cells and thereby generate recombinant retroviruses
[45]. HeLa cells expressing mCAT1 were infected with the recombinant re-
troviruses and selected in medium containing puromycin (5 μg/ml).
2.10. RNA interference
The pMX-puro II vector in which the U3 portion of the 3′-long terminal
repeat was deleted was kindly provided by Dr. T. Kamura (Nagoya University).
The mouse U6 gene promoter followed by DNA corresponding to a short-
hairpin (sh) RNA sequence was subcloned into the NotI and XhoI sites of pMX-
puro II, yielding pMX-puro II-U6/siRNA. The DNA for the shRNA encoded a
21-nucleotide hairpin sequence specific to the mRNA target, with a loop se-
quence (5′-TTCAAGAGA-3′) separating the two complementary domains, and
contained a tract of five T nucleotides to terminate transcription. The hairpin
sequences specific for human Ymer and for EGFP (Clontech) mRNAs corres-
ponded to nucleotides 609 to 628 (Ymer-1) and 149 to 168 (Ymer-2) of the
respective coding regions. Recombinant retroviruses were generated and used to
infect HeLa cells as described above. After selection in medium containing
puromycin (5 μg/ml), the resulting cells were checked by immunoblot analysis
with anti-Ymer antibody.
2.11. Luciferase assay
Ba/F3 cells stably expressing a κB luciferase reporter were transfected with
expression vectors encoding Ymer and A20 by electroporation (1040 μF and
0.3 kV) and inoculated into a 24-well dish at 1×106 cells/500 μl of cell culture
medium, and then LPS was added 24 h after transfection. After stimulation at
37 °C for 4 h, cells were harvested and lysed in 50 μl of cell culture lysis reagent
(Promega), and then luciferase activity was measured using 20 μl of lysate and
100 μl of luciferase assay substrate (Promega). The luminescence was quantified
with a luminometer (Berthold Japan, Tokyo, Japan). HeLa cells were transfected
with expression vectors encoding Ymer, YmerL116P, A20, IKKβ, IKKγ, or
RIP1 together with pRL-TK (Promega) as an internal control and pκB-TK-Luc
with the use of FuGENE6 (Roche). The cells were harvested 48 h after trans-
fection, lysed, and assayed for luciferase activity with a Dual-Luciferase Re-
porter Assay System (Promega).
2.12. Statistical analysis
We used the unpaired Student's t test to determine the statistical significance
of experimental data.
2.13. Immunofluorescence staining
HeLa cells grown on a glass cover were fixed for 20 min at room tem-
perature with 4% formaldehyde in PBS and then incubated for 1 h at room
temperature with primary antibodies to A20 and Ymer in PBS containing 0.1%
bovine serum albumin and 0.1% saponin. They were then incubated withAlexa488-labeled goat polyclonal antibodies to mouse immunoglobulin and
Alexa546-labeled goat polyclonal antibodies to rabbit immunoglobulin (Mole-
cular Probes, Eugene, OR) at a dilution of 1:2000 and then stained with
Hoechst33258 (Wako, Osaka, Japan). The cells were covered with a drop of
GEL/MOUNT (Biomeda, Foster City, CA) and then photographed with a CCD
camera (DP71, Olympus) attached to an Olympus BX51 microscope.
3. Results
3.1. Interaction of A20 with Ymer
To identify proteins that bind to A20, we constructed a full-
length A20 cDNA in pBTM116 for yeast two-hybrid screening
using a human B cell cDNA library. Sixty positive clones were
isolated on Leu–Trp–His-deficient medium from 2.5×106
transformants. Several previously reported proteins including,
14-3-3α, 14-3-3β and ABIN-1/2 [20,21], and one novel protein,
Ymer (accession number: AJ416916), were isolated. Next, we
examined the interaction between A20 and Ymer in HEK293T
cells. Immunoprecipitation and immunoblot analysis revealed
that HA-tagged A20 interacted with FLAG-tagged Ymer
(Fig. 1A). We also verified interaction between endogenous
A20 and endogenous Ymer by anti-A20 and anti-Ymer anti-
bodies (Fig. 1B). Next, we examined the intracellular locali-
zation of A20 and Ymer by immunostaining using HeLa cells.
Immunofluorescence staining showed that both A20 and Ymer
partially localized in the cytosol (Fig. 1C).
To examine the region for binding of A20 to Ymer, we
performed an in vivo binding assay using truncated forms of
A20, including A20(1–90), A20(1–305), A20(1–516), A20
(91–305) and A20(338–790)/ZnF1–7 (Fig. 1D). We first con-
structed two HA-fused mutants, A20(1–516) and A20ZnF1–7,
and transiently expressed each of these and full-length FLAG-
tagged Ymer in HEK293T cells. Each of the immunoprecipi-
tates prepared with anti-FLAG beads was analyzed by Western
blotting with anti-HA or anti-FLAG antibodies. Ymer inter-
acted with A20(1–516) and A20(WT) but not with A20ZnF1–7
(Fig. 1E). Then we detected interaction of Ymer with A20(1–
305), A20(91–305) and A20(WT) (Fig. 1F). These results in-
dicate that amino acid residues 91–305, which include the OTU
domain, are required for binding of A20 to Ymer.
3.2. Interaction of Ymer with K63-linked polyubiquitin chain
To identify proteins binding to Ymer, we performed yeast
two-hybrid screening using full-length human Ymer cDNA as a
bait. Eight positive cDNA clones isolated from 1.8×106 trans-
formants were several types of ubiquitin cDNA. An in vitro
pull-down assay also verified that K63-linked polyubiquitin
chains bound the wild type of Ymer (Fig. 2A). Ubiquitin has
seven lysine residues, and all of them are possibly involved in
chain formation, but so far mainly K48- and K63-linked poly-
ubiquitin chains are functionally characterized [22]. The K48-
linked polyubiquitin chain contributes to proteasomal degrada-
tion, while the K63-linked polyubiquitin chain mediates cell
signaling, DNA repair, DNA translation, endocytosis and ve-
sicle transport [23]. It has been reported that molecules in
association with the NF-κB signaling pathway, such as A20,
Fig. 1. Ymer interacts with A20. (A) Interaction between Ymer and A20 in HEK293T cells. HEK293T cells were transfected with expression plasmids encoding
FLAG-tagged Ymer and HA-tagged A20 as indicated. Cells were lysed and subjected to immunoprecipitation (IP) with anti-FLAG antibody, and the resulting
precipitates were subjected to immunoblot (IB) analysis with anti-HA or anti-FLAG antibody. A portion of the cell lysate corresponding to 3% of the input for IP was
also subjected to IB analysis. WCL: whole cell lysate. (B) Interaction between endogenous Ymer and endogenous A20 in Jurkat cells. Jurkat cells were lysed and
subjected to IP with anti-Ymer antibody, and the resulting precipitates were subjected to IB analysis with anti-A20 or anti-Ymer antibody. (C) Immunofluorescence
analysis of A20 and Ymer. HeLa cells were incubated with anti-A20 (mouse) or anti-Ymer (rabbit) antibodies. They were reacted with Alexa488-labeled goat
polyclonal antibodies to mouse immunoglobulin and Alexa546-labeled goat polyclonal antibodies to rabbit immunoglobulin and then stained with Hoechst33258 to
visualize the nuclei. (D) Schematic representation of mutants and truncates of A20. Gray box: OTU domain, black box: zinc finger domain. (E) Region for binding of
A20 with Ymer. Expression vectors with either HA-tagged wild-type A20, A20(1–516) or A20(ZnF1–7) and FLAG-tagged Ymer were transfected into HEK293T
cells, and then cell lysates were immunoprecipitated with anti-FLAG antibody, and anti-HA or anti-FLAG IB analysis was performed to detect interaction between
A20 and Ymer. (F) Intracellular binding of truncated A20 and Ymer. Expression vectors with either HA-tagged wild-type A20, A20(1–90), A20(1–306) or A20(90–
306) and FLAG-tagged Ymer were transfected into HEK293T cells, and then cell lysates were immunoprecipitated with anti-FLAG antibody, and anti-HA or anti-
FLAG IB analysis was performed to detect interaction between A20 and Ymer.
829M. Bohgaki et al. / Biochimica et Biophysica Acta 1783 (2008) 826–837IKKγ (also known as NF-κB essential modulator: NEMO) and
familial cylindromatosis tumor suppressor gene (CYLD), inter-
act with the K63-linked polyubiquitin chain [12]. We also found
that Ymer has a K63-linked ubiquitin binding motif like that of
IKKγ (Fig. 2B). To verify binding between Ymer and ubiquitin,
we performed an in vitro binding assay using truncated forms of
Ymer, including Ymer1–64, Ymer1–146, and YmerΔ65–134.
The region including the amino acid residue 65–134 of Ymer
was indispensable for the recognition of K63-linked poly-
ubiquitin chain (Fig. 2C, D). To further confirm the region for
binding of Ymer with K63-linked ubiquitin, an in vitro pull-
down assay was performed using YmerL116P, in which leucine
was substituted for proline at position 116. YmerL116P weaklyinteracted with the K63-linked polyubiquitin chain (Fig. 2E). It
has been previously reported that the equivalent mutation in
IKKγ(L329P) prevents binding for K63-linked polyubiquitin
[12]. The results indicated that the region including leucine-116
of Ymer was crucial for recognition of the K63-linked poly-
ubiquitin chain.
3.3. Effect of Ymer on interaction between A20 and K63-linked
polyubiquitin
We demonstrated that the region including residues 91–305
of A20 is necessary for interaction with Ymer (Fig. 1E), and this
region has been reported to recognize and disrupt K63-linked
Fig. 2. Ymer interacts with K63-linked polyubiquitin chain. (A) Analysis for the ability to interact with K48- or K63-linked polyubiquitin chain. The indicated
combinations of proteins were subjected to IP with anti-GST, and the resulting precipitates were subjected to IB analysis with anti-ubiquitin and anti-GST. A portion
(5% of the input for IP) of each binding mixture was also subjected directly to IB analysis. (B) Comparison of the ubiquitin-binding motifs of IKKγ and Ymer. A K63-
linked polyubiquitin-binding motif of IKKγ is similar to the amino acid residues in the coiled-coil domain of Ymer. Similar sequences are underlined. (C) Schematic
representation of mutants and truncates of Ymer. (D) Region for binding of Ymer with K63-linked polyubiquitin chain. The indicated combinations of proteins were
subjected to IP with anti-GST, and the resulting precipitates were subjected to IB analysis with anti-ubiquitin and anti-GST. (E) YmerL116P does not interact with the
K63-linked polyubiquitin chain. The indicated combinations of proteins were subjected to IP with anti-GST, and the resulting precipitates were subjected to IB analysis
with anti-ubiquitin and anti-GST.
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quitin-binding region of Ymer is required for interaction with
A20, we performed an in vivo binding assay using either FLAG-
tagged YmerΔ65–134 or full-length Ymer and HA-tagged full-
length A20, and we found that YmerΔ65–134 was incapable of
association with A20, suggesting that the ubiquitin-binding
region of Ymer is also an A20-binding region (Fig. 3A). In
addition, to determine whether Ymer enhances interaction be-
tween A20 and the K63-linked polyubiquitin, we performed an
in vitro binding assay using recombinant A20, K63-linked
polyubiquitin and Ymer. The in vitro binding assay showed that
A20 alone associates with the K63 polyubiquitin chain and thatthe association is enhanced in the presence of Ymer (Fig. 3B).
These findings suggest that the ubiquitin-binding region of
Ymer functions as a scaffold between A20 and K63-linked
polyubiquitin.
3.4. Interaction of Ymer with RIP1
Previous studies have shown that RIP1 is ubiquitinated with
the K63-linked polyubiquitin chain and that A20 hydrolyses the
K63-linked polyubiquitin chain on RIP1 via OTU domain and
attenuates TNF-induced NF-κB signaling [11]. To determine
whether Ymer recognizes RIP1, IKKγ or TRAFs, we transfected
Fig. 3. Effect of Ymer on interaction between A20 and K63-linked
polyubiquitin. (A) Intracellular binding of A20 with truncated Ymer. Expression
vectors with either FLAG-tagged wild-type Ymer or YmerΔ65–134 and HA-
tagged wild-type A20 were transfected into HEK293Tcells, and then cell lysates
were immunoprecipitated with anti-FLAG antibody, and anti-HA or anti-FLAG
IB analysis was performed to detect interaction between A20 and Ymer.
(B) Effect of Ymer on interaction between A20 and K63-linked polyubiquitin
chain. The indicated combinations of proteins were subjected to IP with anti-A20,
and the resulting precipitates were subjected to IB analysis with anti-ubiquitin. A
portion (5% of the input for IP) of each binding mixture was also subjected directly
to IB analysis with anti-ubiquitin, anti-A20 and anti-Ymer antibodies.
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either the wild-type Ymer or mock. The immunoprecipitates
with antibodies to Ymer contained RIP1 (Fig. 4A), IKKα and
IKKβ but not IKKγ or TRAFs (data not shown). Overex-
pression of Ymer caused a decrease in the expression level of
RIP1, even though the expression level of mRNA of RIP1 with
co-transfection of Ymer is almost the same, compared to that
without co-transfection of Ymer (Fig. 4A, B), suggesting that
Ymer promotes the degradation of RIP1. We also verified in-
teraction between endogenous RIP1 and endogenous Ymer by
using anti-RIP1 and anti-Ymer antibodies (Fig. 4C).
Next, we performed an in vivo binding assay using FLAG-
tagged truncated mutants of Ymer, including Ymer1–146, and
YmerΔ65–134 with HA-tagged RIP1. The interactions of RIP1
with truncated mutants of Ymer were weaker than that with the
wild type of Ymer, suggesting that Ymer probably associates
with RIP1 not only by the ubiquitin-binding region (65–134
amino acids) of Ymer but also by N-terminal other region of
Ymer (Fig. 4D). To further ascertain RIP1 binding activity of
Ymer, we performed an in vitro binding assay using GST-
tagged Ymer and His-tagged ubiquitinated RIP1 or unubiqui-
tinated RIP1. Recombinant RIP1 was ubiquitinated by E1,Ubc13/ Uev1A and TRAF6 (Fig. 4E). An in vitro binding assay
showed that Ymer interacts with RIP1, regardless of whether
RIP1 is ubiquitinated or not (Fig. 4F).
Next, to examine the effect of Ymer on the degradation of
RIP1 in vivo, we transfected HEK293T cells with FLAG-tagged
RIP1 and with either wild-type Ymer or YmerL116P, the ubi-
quitin-binding activity of which is diminished. Wild-type Ymer
remarkably decreased the expression levels of RIP1, but Ymer
L116P did not, even though the expression levels of mRNA of
RIP1 with co-transfection of each type of Ymer were almost the
same (Fig. 4G). To further confirm the effect of Ymer on the
degradation of RIP1 in vivo, HEK293T cells were transfected
with vectors for FLAG-tagged RIP1 and for either the wild type
or L116P mutant of Myc-tagged Ymer, and the cells were
cultured with cycloheximide and then cell lysates at indicated
times were analyzed by immunoblotting with anti-FLAG. Pulse-
chase analysis revealed that the expression of wild-type Ymer
promoted the degradation of RIP1 in vivo but YmerL116P did
not (Fig. 4H). To determine whether the degradation of RIP1 by
Ymer is dependent on proteasome activity, pulse-chase analysis
was performed using the proteasome inhibitors MG132 and
LLnL and the lysosomal inhibitors NH4Cl and chloroquine.
Pulse-chase analysis showed that proteasomal inhibitors inhib-
ited the degradation of RIP1 by overexpression of Ymer but that
lysosomal inhibitors did not (Fig. 4I). When the cells were lysed,
Laemmli buffer containing 25 mM Tris–HCl (pH 8.3), 192 mM
glycine, and 0.1% SDS, which solubilizes an NP-40-insoluble
compartment, was used to rule out the possibility of translo-
cation of RIP1 to an NP-40-insoluble compartment. To further
confirm that Ymer-regulated RIP1 downregulation occurs
through the proteasomal pathways, we used a stably Ymer-
overexpressing Jurkat cell line (Fig. 4J). The expression level of
endogenous RIP1 was recovered with the proteasome inhibitor
lactacystin but not recovered with the lysosomal inhibitor
chloroquine. These findings indicate that the stability of RIP1 is
regulated by ubiquitin-binding activity of Ymer and proteasomal
activity.
3.5. Inhibition of NF-κB signaling by Ymer
A20 is known as a TNFα-induced protein and a negative
regulator of NF-κB signaling, whereas RIP1 is known as a
positive mediator. To determine whether Ymer functions with
A20 positively or negatively, we examined its effect on the
relative luciferase activity by NF-κB. We transfected an NF-κB-
dependent luciferase reporter vector into HeLa cells with an
expression vector for Ymer or A20 and then stimulated the cells
with human recombinant TNFα. The TNFα-induced transacti-
vation of a luciferase reporter gene by NF-κB was inhibited in
Ymer-transfected cells and A20-transfected cells, as previously
reported (Fig. 5A). Also, in mouse B cell line Ba/F3 cells, Ymer
and/or A20 attenuated the NF-κB activity against lipopolysac-
charide (LPS) stimulation (Fig. 5B). To determine whether the
ubiquitin-binding region of Ymer affects the NF-κB inhibition,
we transfected an NF-κB-dependent luciferase reporter vector
into HeLa cells with an expression vector for wild-type Ymer or
YmerL116P and then stimulated the cells with TNFα. Ymer
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with that of wild-type Ymer (Fig. 5C). It has been reported that
either mutants of the OTU domain (A20C103A) or zinc finger(ZnF) domain (A20ZnF4) of A20 are incapable of inhibiting
NF-κB signaling [11]. We transfected an NF-κB-dependent
luciferase reporter vector into HeLa cells with an expression
833M. Bohgaki et al. / Biochimica et Biophysica Acta 1783 (2008) 826–837vector for Ymer, wild-type A20, A20C103A or A20ZnF4. The
combination of Ymer and wild-type A20 inhibited the NF-κB
signaling even more, whereas A20C103A or A20ZnF4 did not
enhance the inhibitory effect of Ymer, indicating that both of
OTU domain and ZnF domain of A20 are likely to be required to
inhibit NF-κB signaling in collaboration with Ymer (Fig. 5D).
Co-transfection of Ymer attenuated the NF-κB activation in-
duced by overexpression of RIP1, while the inhibitory action
of Ymer was ineffective on IKKβ-induced activation, indi-
cating that Ymer is likely to be an upstream molecule of IKKβ
(Fig. 5E, F). These findings indicated that Ymer reduces the
extent of NF-κB transactivation induced by TNFα stimulation
or overexpression of RIP1 in collaboration with A20.
3.6. Knock-down of endogenous Ymer
To determine whether the abundance of endogenous Ymer
affects the activity of NF-κB signaling, we used RNA inter-
ference (RNAi) to knock down endogenous Ymer in HeLa cells
(siYmer-1 and siYmer-2) (Fig. 6A). The depletion of endoge-
nous Ymer resulted in an increase in the expression level of
RIP1, regardless of the high expression level of A20, which
degrades RIP1 by the ubiquitin–proteasome pathway (Fig. 6B).
The reason for increased expression of A20 is probably because
increased RIP1 activates NF-κB signal and results in upregula-
tion of transcription of A20 which is known to be induced by
activation of NF-κB. Given that the K63-linked polyubiquitin
chain on RIP1 interacts with A20 [11] or IKKγ, it is possible that
Ymer affects the binding between RIP1 and IKKγ. We per-
formed an in vivo binding assay using cells in which Ymer was
stably knocked down. Depletion of Ymer enhanced the inter-
action between IKKγ and ubiquitinated RIP1 after TNFα sti-
mulation (Fig. 6C). These results indicate the possibility that
Ymer interferes with the interaction between IKKγ and K63-
linked polyubiquitin chain on RIP1. To examine the effect by theFig. 4. Ymer interacts with RIP1. (A) Interaction between Ymer and RIP1 in HEK2
Myc-tagged Ymer and HA-tagged RIP1 as indicated. Cells were lysed and subjected
analysis with anti-HA or anti-Myc antibody. (B) The abundance of mRNAs for HA-RI
was determined by RT-PCR. The 5′-primer for HA-RIP1 was designed in the HA-tag
Jurkat cells. Jurkat cells were lysed and subjected to IP with anti-Ymer antibody, an
Ymer antibody. (D) Possibility of a region other than the ubiquitin-binding motif in
with expression plasmids encoding FLAG-tagged wild-type or truncated Ymer (Yme
subjected to IP with anti-Myc antibody, and the resulting precipitates were subjected
corresponding to 3% of the input for IP was also subjected to IB analysis. (E) In v
presence of ubiquitin, E1 and E2 (Uev1A and Ubc13) with or without ATP at 30 °C fo
RIP1. The indicated combinations of proteins were subjected to IP with anti-GST, an
GST. A portion (5% of the input for IP) of each binding mixture and ubiquitinated or u
RIP1 degradation by Ymer. HEK293T cells were transfected with expression plasmid
RIP1 as indicated. Cells were lysed and subjected to IB analysis with anti-HA anti
mRNAs for HA-RIP1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; i
analysis of RIP1 with Ymer. HEK293Tcells were transfected with expression plasmid
tagged YmerL116P or the mock (empty vector). Twenty-four hours after transfectio
indicated times. Cell lysates were then subjected to immunoblot analysis with anti-FL
by Ymer. HEK293T cells were transfected with expression plasmids encoding FLA
vector). Twenty-four hours after transfection, the cells were cultured in the presence o
(100 μM), lactacystin (10 μM), NH4Cl (20 mM) and chloroquine (200 μM), for 6 h. C
actin and anti-Myc antibodies. (J) Stability of RIP1 using stably Ymer-overexpress
presence of LLnL (100 μM) or chloroquine (200 μM) for 12 h. Cell lysates were the
antibodies.depletion of Ymer on RIP1-dependent NF-κB transactivation,
we performed a relative luciferase assay for NF-κB. The relative
luciferase activities of cells transfected with Ymer siRNAwere
increased compared to that of cells transfected with the control
siRNA, even without stimulation by TNFα or overexpression of
IKKβ, suggesting that the release from inhibition by Ymer
expedites NF-κB activity (Fig. 6D). TNFα is likely to be an
upstream molecule of Ymer, and RIP1 was probably fully acti-
vated in siYmer cells already without stimulation. Thus, addition
of TNFαmay not have enhanced NF-κB activity in siYmer cells.
However, since IKKβ is likely to be a downstream molecule of
Ymer, overexpression of IKKβ could more enhance NF-κB
activity in siYmer cells (Fig. 6D). Moreover, overexpression of
Ymer in cells with Ymer knocked down by siRNA resulted in
recovery of the inhibitory effect for NF-κB activity, indicating
that the effect by RNAi for Ymer is specific (Fig. 6E).
4. Discussion
We identified Ymer as a novel K63-linked polyubiquitin
chain-binding protein. Ymer was first identified as a gene en-
coded in chromosome 3 open reading frame 6 (C3orf6), mapped
to chromosome 3q28, within the critical region of hereditary
spastic paraplegia SPD14 locus [24]. Ymer has also been cha-
racterized as a tyrosine-phosphorylated protein by stimulation
of epidermal growth factor (EGF), and Ymer is therefore pre-
sumed to be closely related to growth factor signaling or car-
cinogenesis [25–28]. With EGF stimulation, the functional
phosphorylated site of Ymer has been identified as tyrosine-145
and 146 [25–28]. Furthermore, Ymer has been reported to be
bound to mono- or multiubiquitin on an activated EGF receptor,
and K129 of Ymer has been identified as a ubiquitination site
[27]. Ubiquitination of the EGF receptor has been shown to be a
significant regulator for endocytosis or degradation. Phosphor-
ylated Ymer is located at the plasma membrane with EGF93T cells. HEK293T cells were transfected with expression plasmids encoding
to IP with anti-Myc antibody, and the resulting precipitates were subjected to IB
P1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; internal standard)
sequence. (C) Interaction between endogenous Ymer and endogenous RIP1 in
d the resulting precipitates were subjected to IB analysis with anti-RIP1 or anti-
Ymer for interaction between Ymer and RIP1. HEK293T cells were transfected
r1–146, YmerΔ65–134) and HA-tagged RIP1 as indicated. Cells were lysed and
to IB analysis with anti-HA or anti-FLAG antibody. A portion of the cell lysate
itro ubiquitination on RIP1. Recombinant His-tagged RIP1 was reacted in the
r 16 h. (F) The ability of Ymer to interact with K63-linked polyubiquitin chain on
d the resulting precipitates were subjected to IB analysis with anti-RIP and anti-
nubiquitinated RIP1 was also subjected directly to IB analysis. (G) Promotion of
s encoding either Myc-tagged wild-type of Ymer or YmerL116P and HA-tagged
body. Anti-HSP90 antibody was used as an internal control. The abundance of
nternal standard) was determined by RT-PCR (lower panels). (H) Pulse-chase
s encoding FLAG-tagged RIP1 and either Myc-tagged wild type of Ymer, Myc-
n, the cells were cultured in the presence of cycloheximide (50 μg/ml) for the
AG, anti-β-actin and anti-Myc antibodies. (I) Proteasomal degradation of RIP1
G-tagged RIP1 and either Myc-tagged wild type of Ymer or the mock (empty
f cycloheximide (50 μg/ml) and one of drugs including MG132 (10 μM), LLnL
ell lysates were then subjected to immunoblot analysis with anti-FLAG, anti-β-
ing Jurkat cells. Stably Ymer-overexpressing Jurkat cells were cultured in the
n subjected to immunoblot analysis with anti-RIP1, anti-β-actin and anti-FLAG
Fig. 5. Ymer attenuates NF-κB transcriptional activity. (A) Ymer reduces TNFα-induced NF-κB activity in a dose-dependent manner. HeLa cells were transfected with
the κB luciferase reporter plasmid and expression plasmids encoding Ymer and A20 as indicated. Twenty-four hours after transfection, cells were treated with TNFα
(10 ng/μl) and cultured for an additional 6 h. (B) Effect of Ymer on LPS-induced NF-κB activity in Ba/F3 cells. Ba/F3 cells stably expressing human TLR4, human
MD2, human CD14 and a reporter gene with the NF-κB promoter were transfected with indicated plasmids. Twenty-four hours after transfection, cells were treated
with LPS and cultured for an additional 4 h. The P values for the indicated comparisons were determined by Student's t test. (C) Role of domains in Ymer for TNFα-
induced NF-κB activity. HeLa cells were transfected with κB luciferase reporter plasmid and expression plasmids encoding wild-type or YmerL116P as indicated.
Twenty-four hours after transfection, cells were treated with TNFα (10 ng/μl) and cultured for an additional 6 h. (D) Ymer collaborates with A20 for negative
regulation of TNFα-induced NF-κB activation. HeLa cells were transfected with κB luciferase reporter plasmid and expression plasmids encoding Ymer and wild-type
or mutant A20 (A20C103A, A20ZnF4) as indicated. Twenty-four hours after transfection, cells were treated with TNFα (10 ng/μl) and cultured for an additional 6 h.
The P values for the indicated comparisons were determined by Student's t test. (E) Ymer reduces RIP1-induced NF-κB activity. HeLa cells were transfected with the
κB luciferase reporter plasmid and expression plasmids encoding Ymer and RIP1 as indicated. Forty-eight hours after transfection, κB luciferase activity was assayed.
(F) Ymer does not affect IKKβ-induced NF-κB activity. HeLa cells were transfected with the κB luciferase reporter plasmid and expression plasmids encoding Ymer
and IKKβ as indicated. Forty-eight hours after transfection, κB luciferase activity was assayed.
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EGF receptor is inhibited by Ymer, suggesting that Ymer is a
negative regulator of the EGF signaling pathway. Moreover, our
findings demonstrated a new aspect of Ymer as a protein bind-
ing to the K63-linked polyubiquitin chain in the NF-κB sig-
naling pathway.
The formation of a polyubiquitin chain by linkage of the
COOH-terminus of one ubiquitin moiety to K48 of the adjacentubiquitin had been thought to mark a protein for proteolysis by
the 26S proteasome. However, recent observations indicate that
polyubiquitin chains can also be assembled through conjuga-
tion to lysine residues of ubiquitin other than K48, and the
resulting chains appear to function in distinct biological pro-
cesses [29]. A short K29-linked chain might thus constitute a
signal to recruit E4 before proteasomal proteolysis [30]. Poly-
ubiquitination through K63 of ubiquitin appears to mark
Fig. 6. Knock-down of Ymer promotes NF-κB activity. (A) Knock-down of Ymer by RNAi. HeLa cells were infected with the indicated siRNA vectors by retroviral
systems. Cell lysates were subjected to immunoblotting using anti-Ymer or anti-HSP90 antibodies. (B) Ymer RNAi increases the expression levels of RIP1 and A20.
Each cell lysate was subjected to immunoblotting using anti-RIP1, anti-A20, anti-β-actin or anti-Ymer antibodies. (C) Ymer RNAi enhances the interaction between
ubiquitinated RIP1 and IKKγ. A stably knocked-down HeLa cell line (siYmer-1) was stimulated by TNFα at the indicated time, and then cells were lysed and
subjected to IP with anti-IKKγ antibody, and the resulting precipitates were subjected to IB analysis with anti-RIP. (D) Ymer RNAi induces transcriptional activity of
NF-κB. Knocked-down HeLa cell lines (siYmer-1 and siYmer-2) and a mock cell line (siEGFP) were transfected with the κB luciferase vector and expression vectors
encoding IKKβ or mock cDNA. Twenty-four hours after transfection, cells were treated with TNFα (10 ng/μl), cultured for an additional 6 h, and then κB luciferase
activity was assayed. (E) Up-regulated NF-κB activity induced by knock-down of Ymer was suppressed by overexpression of Ymer. The siEGFP and siYmer-1 cell
lines were further transfected with the κB luciferase vector and the expression vector encoding Ymer. Forty-eight hours after transfection, κB luciferase activity was
assayed. The averages and standard deviations were calculated from three independent experiments.
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to stress, to inheritance of mitochondrial DNA, to endocytosis
of certain plasma membrane proteins, or to ribosomal function
[31–35]. In addition, TRAF6, a RING finger-type E3, in con-
junction with the E2 Ubc13 and the Ubc-like protein Uev1A,
targets K63 of ubiquitin and plays an important role in IκB
phosphorylation in the NF-κB signaling pathway [36]. RIP1,
IKKγ and TRAF6 are modified by K63-linked polyubiquitin,
and this modification activates the IKK complexes, ultimately
leading to the translocation of NF-κB to the nucleus.
To date several molecules that down-regulate NF-κB activity,
coupled with A20, have been identified. Our results indicate that
the interaction of Ymer with the K63-linked polyubiquitin chain
on RIP1 dampens NF-κB signaling. It has been reported that the
interaction of IKKγ with the K63-linked polyubiquitin chain on
RIP1 advances NF-κB activation [9,12]. Since IKKγ and Ymer
can interact with the K63-linked polyubiquitin chain on RIP1,
our findings indicate that Ymer competes with the interaction
between IKKγ and RIP1, resulting in the attenuation of NF-κBsignaling. Furthermore, Ymer can directly interact with even
RIP1 without conjugation of the ubiquitin chain and inhibit
its function. Thus, knock-down of Ymer caused activation of
NF-κB signaling without stimulation. Taken together, the find-
ings suggest that Ymer and IKKγ are sensors of K63-linked
polyubiquitination of proximal molecules in receptor-mediated
signaling but that each function reversely, probably providing a
crucial mechanism for NF-κB signal activation.
NF-κB is likely to seal the destiny depending on each
circumstance of the cells. NF-κB signaling results in cell death
in some cases, while NF-κB activation often suppresses cell
death under other conditions. Therefore, depending on the cell
type in which NF-κB acts, NF-κB can either promote or inhibit
carcinogenesis and cancer progression. In chemical-induced
skin or liver cancer models, inhibition of NF-κB promotes
tumorigenesis [37], and IKKγ-deficient rat fibroblast cells (5R
cells) form colonies on a soft agar and cause the development of
tumors in nude mice [38]. A previous study has suggested that
the anti-tumorigenic activity of NF-κB depends on inhibition of
836 M. Bohgaki et al. / Biochimica et Biophysica Acta 1783 (2008) 826–837cell cycle progression and/or down-regulation of JNK [39].
Activation of IKK leads to nuclear translocation of NF-κB and
upregulation of several anti-apoptotic genes, including the gene
encoding c-FLICE-inhibitory protein (FLIP), which is a specific
inhibitor of caspase 8 activation. However, the complex in-
cluding TRADD, RIP1 and TRAF2/5 is associated with the
adaptor protein FADD and can recruit and activate caspase 8,
followed by the induction of apoptosis. The balance between
the expression level of FLIP and the activity of caspase 8 may
decide cell fate. However, we could not show that overexpres-
sion of Ymer upregulates the expression level of FLIP (data not
shown). Thus, the functional interaction of Ymer with FLIP or
caspase 8 remains to be analyzed. Furthermore, analysis by a
genetic approach using transgenic or knock-out mice is needed
to determine whether Ymer promotes cell-cycle progression or
suppresses apoptosis.
The failure of regulation of NF-κB is implicated in the etio-
logy of inappropriate immunity such as autoimmune diseases,
inflammation, stress responses and cell death. Recently, the
proteasome inhibitor Bortezomib (Velcade), one function of
which is NF-κB inhibition through reduced IκB degradation,
leading to reduced NF-κB-dependent synthesis of anti-apoptotic
factors, has been evaluated in a number of published and on-
going trials for solid and hematological malignancies [40].
Moreover, it has been reported that the IKKβ inhibitor MLN
120B inhibits TNFα-induced NF-κB activation, resulting in the
inhibition of growth of multiple myeloma cell lines [41]. Further
functional analysis of Ymer may prove to provide therapeutic
benefits not only for the suppression in autoimmune diseases but
also for the inhibition of growth of cancer cells.
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